Fig. 3.
IL-4 stimulation activates ArgLong2 peptide-specific T cells. a IFNγ ELISPOT for ArgLong2 peptide responses in melanoma patient PBMCs stimulated with IL-4 and/or IL-2 for 1 week. Non-stimulated PBMCs used as control. Superimposed bars show the mean counts of IFNγ-producing cells in control (white bars) and peptide-stimulated (grey bars) wells + standard error of the mean. Experiment performed in triplicate with 3 × 105 cells/well. b ArgLong2 peptide-specific responses in PBMCs from six healthy donors (HDs) and two cancer patients (BC, breast cancer; MM, malignant melanoma) after stimulation with IL-4 (100 U/ml) for 1 week. Cells without cytokine stimulation were used as control. Responses calculated as the difference in mean counts of IFNγ-secreting cells between peptide-stimulated and control wells in ELISPOT. Experiment performed in triplicate or in duplicate with 3 × 105 cells/well